SystImmune Inc.
SystImmune Inc. is a biopharmaceutical company focused on developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for the treatment of cancer. The company aims to create biologics that work through systematic intervention on tumor microenvironments, directly attacking tumors and activating the immune system. It is a clinical-stage biotech with ongoing research, development, and clinical trials, and is part of the Sichuan Biokin Pharmaceutical Co., Ltd group. SystImmune leverages advanced technology platforms to develop world-class antibody-based drug therapies, with a global clinical development strategy targeting US and Asian markets.
Industries
Nr. of Employees
small (1-50)
Patents
Guidance and Navigation Control proteins and method of making and using thereof
US-12029761-B2
View Details
Guidance and Navigation Control proteins and method of making and using thereof
US-12029761-B2
View DetailsProducts
Multispecific antibody therapeutics
Therapeutic multispecific and tetra-specific antibody candidates designed to engage multiple tumor-associated targets and modulate tumor signaling or immune responses for oncology indications.
Antibody–drug conjugates (ADC) for solid tumors
Monospecific and bispecific ADC candidates that combine antibody targeting domains with cytotoxic payloads and linker chemistries, intended for indications such as HER2+, TROP2+, EGFR/HER3+ and claudin 18.2-expressing tumors.
Multispecific antibody therapeutics
Therapeutic multispecific and tetra-specific antibody candidates designed to engage multiple tumor-associated targets and modulate tumor signaling or immune responses for oncology indications.
Antibody–drug conjugates (ADC) for solid tumors
Monospecific and bispecific ADC candidates that combine antibody targeting domains with cytotoxic payloads and linker chemistries, intended for indications such as HER2+, TROP2+, EGFR/HER3+ and claudin 18.2-expressing tumors.
Expertise Areas
- Therapeutic antibody discovery
- Bispecific and multispecific antibody engineering
- Antibody–drug conjugate (ADC) development
- Preclinical tumor efficacy evaluation
Key Technologies
- Yeast-display library screening
- B-cell sorting and flow cytometry (FACS)
- Next-generation sequencing for BCR analysis
- Biolayer interferometry (BLI)
News & Updates
Presentation on a filter-based aggregate removal strategy using Virosart® Max filter to remove protein aggregates from biologic drug products, demonstrating a simple, robust, and cost-effective alternative to chromatography.
Presentation of clinical data from phase II studies of SI-B001, a bispecific antibody targeting EGFR and HER3, in cancer treatment.
Presentation on the anti-tumor efficacy of SI-B001, a bispecific antibody targeting EGFR and HER3.
Presentation on BL-M07D1, an antibody-drug conjugate targeting HER2, with details on its mechanism and clinical evaluation.
Presentation on GNC-038, a tetra-specific antibody, with details on its development and potential.
Presentation on GNC-039, a tetra-specific antibody, with details on its development and potential.
Presentation on a filter-based aggregate removal strategy using Virosart® Max filter to remove protein aggregates from biologic drug products, demonstrating a simple, robust, and cost-effective alternative to chromatography.
Presentation of clinical data from phase II studies of SI-B001, a bispecific antibody targeting EGFR and HER3, in cancer treatment.
Presentation on the anti-tumor efficacy of SI-B001, a bispecific antibody targeting EGFR and HER3.
Presentation on BL-M07D1, an antibody-drug conjugate targeting HER2, with details on its mechanism and clinical evaluation.
Presentation on GNC-038, a tetra-specific antibody, with details on its development and potential.
Presentation on GNC-039, a tetra-specific antibody, with details on its development and potential.